Asthma-on-a-chip developed by Harvard researchers.
The majority of drugs used to treat asthma today are the same ones that were used 50 years ago. New drugs are urgently needed to treat this chronic respiratory disease, which causes nearly 25 million people in the United States alone to wheeze, cough, and find it difficult at best to take a deep breath.
However, finding new treatments is tough as asthma is a patient-specific disease, so what works for one person doesn’t necessarily work for another, and the animal models traditionally used to test new drug candidates often fail to mimic human responses costing tremendous money and time.
Hope for healthier airways may be on the horizon thanks to a Harvard University team that has developed a human airway muscle-on-a-chip that could be used to test new drugs because it accurately mimics the way smooth muscle contracts in the human airway, under normal circumstances and when exposed to asthma triggers. As reported in the journal Lab on a Chip, it also offers a window into the cellular and even subcellular responses within the tissue during an asthmatic event.
The chip, a soft polymer well that is mounted on a glass substrate, contains a planar array of microscale, engineered human airway muscles, designed to mimic the laminar structure of the muscular layers of the human airway.
To mimic a typical allergic asthma response, the team first introduced interleukin-13 (IL-13) to the chip. IL-13 is a natural protein often found in the airway of asthmatic patients that mediates the response of smooth muscle to an allergen.
Then they introduced acetylcholine, a neurotransmitter that causes smooth muscle to contract. Sure enough, the airway muscle on the chip hypercontracted, and the soft chip curled up, in response to higher doses of the neurotransmitter. They achieved the reverse effect as well and triggered the muscle to relax using drugs called β-agonists, which are used in inhalers.
Significantly, the group were able to measure the contractile stress of the muscle tissue as it responded to varying doses of the drugs with the chip offering a simple, reliable and direct way to measure human responses to an asthma trigger.
The team then investigated what happened on a cellular level in response to the IL-13 and confirmed, for example, that the smooth muscle cells grew larger in the presence of IL-13 over time, a structural hallmark of the airways in asthma patients as well. They also documented an increased alignment of actin fibers within smooth muscle cells, which is consistent with the muscle in the airway of asthma patients. Actin fibers are super-thin cellular components involved in muscle contraction.
Next they observed how IL-13 changes the expression of contractile proteins called RhoA proteins, which have been implicated in the asthmatic response, although the details of their activation and signalling have remained elusive. To do this they introduced a drug called HA1077, which is not currently used to treat asthmatic patients, but targets the RhoA pathway. It turns out that the drug made the asthmatic tissue on the chip less sensitive to the asthma trigger, and preliminary tests indicated that using a combined therapy of HA1077 plus a currently approved asthma drug worked better than the single drug alone.
Asthma is one of the top reasons for trips to the emergency room, particularly for children, and a large segment of the asthmatic population doesn’t respond to currently available treatments. The airway muscle-on-a-chip provides an important and exciting new tool for discovering new therapeutic agents.